(Q26747740)

2

0 references

Chenfei Tian

3

0 references

Waner Jiang

4

0 references

Ling Jin

5

0 references

Chenyu Zhang

6

0 references

Xi Chen

Wiley interdisciplinary reviews. RNA

7

0 references

publication date

16 May 2016

0 references

published in

1 reference

Asymmetry in the assembly of the RNAi enzyme complex

PubMed

cites work

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

Preclinical and clinical development of siRNA-based therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

RNA interference in the clinic: challenges and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

Potential clinical applications of siRNA technique: benefits and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

A paradigm shift for extracellular vesicles as small RNA carriers: from cellular waste elimination to therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

Exosomes for targeted siRNA delivery across biological barriers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

RNA Interference (RNAi)-Based Therapeutics: Delivering on the Promise?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

In vitro and in vivo efficacy of SYL040012, a novel siRNA compound for treatment of glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

Safety and efficacy of RNAi therapy for transthyretin amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

Current status of vascular endothelial growth factor inhibition in age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

Toxicological and pharmacokinetic properties of QPI-1007, a chemically modified synthetic siRNA targeting caspase 2 mRNA, following intravitreal injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

First-in-human phase I study of the liposomal RNA interference therapeutic Atu027 in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

Phase 1 dose-escalation study of a siRNA targeting the RTP801 gene in age-related macular degeneration patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

Dose-ranging evaluation of intravitreal siRNA PF-04523655 for diabetic macular edema (the DEGAS study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

Strategies for ocular siRNA delivery: Potential and limitations of non-viral nanocarriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

Pharmacokinetic evaluation of pegaptanib octasodium for the treatment of diabetic edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

RNA Interference and Cancer Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

SiRNA delivery with exosome nanoparticles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

Combinatorial RNA Interference Therapy Prevents Selection of Pre-existing HBV Variants in Human Liver Chimeric Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

Exosomes: extracellular organelles important in intercellular communication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

Exosomes--vesicular carriers for intercellular communication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

Biogenesis and secretion of exosomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

Multivesicular body morphogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

Secretory mechanisms and intercellular transfer of microRNAs in living cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

Ceramide triggers budding of exosome vesicles into multivesicular endosomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

Sumoylated hnRNPA2B1 controls the sorting of miRNAs into exosomes through binding to specific motifs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

An unconventional role for miRNA: let-7 activates Toll-like receptor 7 and causes neurodegeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

Hepatic cell-to-cell transmission of small silencing RNA can extend the therapeutic reach of RNA interference (RNAi).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

Microvesicle-mediated delivery of transforming growth factor β1 siRNA for the suppression of tumor growth in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

Exosomes: Natural Carriers for siRNA Delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

Exosomes in diagnostic and therapeutic applications: biomarker, vaccine and RNA interference delivery vehicle.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

The origin, function, and diagnostic potential of extracellular microRNAs in human body fluids

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

Tumor-secreted miR-214 induces regulatory T cells: a major link between immune evasion and tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

Role of Exosomal Noncoding RNAs in Lung Carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

Exosomal miR-221/222 enhances tamoxifen resistance in recipient ER-positive breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

Functional delivery of viral miRNAs via exosomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

Extracellular circulating viral microRNAs: current knowledge and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

Analysis of viral microRNA exchange via exosomes in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

HCV-induced miR-21 contributes to evasion of host immune system by targeting MyD88 and IRAK1

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

Molecular characterization of dendritic cell-derived exosomes. Selective accumulation of the heat shock protein hsc73.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

Virus-modified exosomes for targeted RNA delivery; a new approach in nanomedicine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

Exosomes containing glycoprotein 350 released by EBV-transformed B cells selectively target B cells through CD21 and block EBV infection in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

Targeted exosome-mediated delivery of opioid receptor Mu siRNA for the treatment of morphine relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

Exosome-mediated delivery of siRNA in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

Electroporation-induced siRNA precipitation obscures the efficiency of siRNA loading into extracellular vesicles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

Quantitative analysis of tissue distribution of the B16BL6-derived exosomes using a streptavidin-lactadherin fusion protein and iodine-125-labeled biotin derivative after intravenous injection in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

Visualization and in vivo tracking of the exosomes of murine melanoma B16-BL6 cells in mice after intravenous injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

Dynamic biodistribution of extracellular vesicles in vivo using a multimodal imaging reporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

Exosomes are natural carriers of exogenous siRNA to human cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

Examination of mesenchymal stem cell-mediated RNAi transfer to Huntington's disease affected neuronal cells for reduction of huntingtin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

Plasma exosomes can deliver exogenous short interfering RNA to monocytes and lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

Enabling a robust scalable manufacturing process for therapeutic exosomes through oncogenic immortalization of human ESC-derived MSCs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

Secreted monocytic miR-150 enhances targeted endothelial cell migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

7 January 2021

Evaluation of the siRNA PF-04523655 versus ranibizumab for the treatment of neovascular age-related macular degeneration (MONET Study)

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

7 January 2021

Secreted microRNAs: a new form of intercellular communication

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

7 January 2021

Are RNAi and miRNA therapeutics truly dead?

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

7 January 2021

Exosomes: composition, biogenesis and function

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

7 January 2021

Toxicological and pharmacokinetic properties of chemically modified siRNAs targeting p53 RNA following intravenous administration

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

7 January 2021

Functional transfer of microRNA by exosomes

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

7 January 2021

Bevasiranib for the treatment of wet, age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1002%2FWRNA.1363

7 January 2021